Diagnostic algorithm based on ratio of ascites-serum tumor markers is superior to tumor markers in the differentiation of benign ascites from malignant ascites

被引:0
|
作者
Liu, Minghui [1 ]
Zhang, Nan [2 ]
Wei, Xiuqi [3 ]
Xiao, Zhuanglong [1 ]
Song, Yuhu [1 ]
Du, Li [1 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Div Gastroenterol, Wuhan 430022, Peoples R China
[2] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Endocrinol, Wuhan 430022, Peoples R China
[3] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Clin Lab, Wuhan 430022, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
Benign ascites; Malignant ascites; Ascitic tumor markers; Ratio of ascites-serum tumor markers; Diag nosis algorithm; CARCINOEMBRYONIC ANTIGEN; OVARIAN; PERITONITIS; MANAGEMENT; CA-19-9; FLUID; CEA;
D O I
10.1016/j.amjms.2024.06.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Differential diagnosis between benign ascites and malignant ascites remains challenging in clinical practice, the aim of our study is to determine the differential value of the ratio of ascitic-serum tumor markers between benign ascites and malignant ascites. Methods: 418 patients with new-onset ascites were retrospectively enrolled in this study. The pertinent data of patients enrolled were collected; diagnostic value of tumor markers, ascites-serum tumor marker ratio, and diagnostic algorithm based on ascitic tumor markers and ascites-serum tumor marker ratio in patients with ascites were investigated. Results: 81.25% of the patients with benign ascites had low (<1) ratio of ascites-serum tumor markers (Max EA/S CEA, A/S CA15-3, A/S CA19-9]); and 91.88% of patients with benign ascites had the ratio of ascites-serum tumor marker less than 1.5. On the other hand, 94.96% of the patients with malignant ascites had high (>= 1) ratio of ascites-serum tumor markers; and 97.29% of patients with malignant ascites had the ratio of ascites-serum tumor markers more than 0.67. Finally, diagnostic algorithm based on ascitic tumor markers and ascites-serum tumor marker ratio showed 96.37% of the sensitivity, and 94.37% of the accuracy in the diagnosis of malignant ascites, while ascitic tumor markers with a sensitivity of 78.29%, and an accuracy of 84.93%. Conclusions: Diagnostic algorithm based on ascitic tumor markers and ascites-serum tumor marker ratio exhibited an excellent performance in distinguishing benign and malignant ascites, which should be recommended in patients with new-onset ascites in clinical practice.
引用
收藏
页码:361 / 368
页数:8
相关论文
共 50 条
  • [41] Differential Expression of CD3ζ Message and Protein in Tumor Infiltrating Lymphocytes from Solid Tumor Specimens and Malignant Ascites from Patients with Ovarian Carcinoma
    Pappas, John
    Wolfson, Alexey D.
    Jung, Weon J.
    Oleszak, Emilia L.
    Helm, C. William
    Freedman, Ralph S.
    Tsygankov, Alexander Y.
    Platsoucas, Chris D.
    ANTICANCER RESEARCH, 2009, 29 (11) : 4673 - 4682
  • [42] Immunoglobulins and serum proteins impair anti-tumor NK cell effector functions in malignant ascites (vol 15, 1420991, 2024)
    Hrvat, Antonio
    Benders, Sonja
    Kimmig, Rainer
    Brandau, Sven
    Mallmann-Gottschalk, Nina
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [43] INVIVO RELEASE OF GLYCOPROTEIN I FROM HA SUBLINE OF TA3 MURINE TUMOR INTO ASCITES FLUID AND SERUM
    COOPER, AG
    CODINGTON, JF
    BROWN, MC
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1974, 71 (04) : 1224 - 1228
  • [44] Serum and pancreatic juice tumor markers in patients with benign and malignant mucin-secreting and cystic tumors of the pancreas
    Kalayci, C
    Catalano, M
    Fraiberg, E
    Goff, J
    Fogel, E
    Dayrit, P
    GASTROINTESTINAL ENDOSCOPY, 1999, 49 (04) : AB56 - AB56
  • [45] The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients
    Di, Jiabo
    Duiveman-de Boer, Tjitske
    Zusterzeel, Petra L. M.
    Figdor, Carl G.
    Massuger, Leon F. A. G.
    Torensma, Ruurd
    CELLULAR ONCOLOGY, 2013, 36 (05) : 363 - 374
  • [46] The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients
    Jiabo Di
    Tjitske Duiveman-de Boer
    Petra L. M. Zusterzeel
    Carl G. Figdor
    Leon F. A. G Massuger
    Ruurd Torensma
    Cellular Oncology, 2013, 36 : 363 - 374
  • [47] EpCAM plus tumor cells are detected in malignant ascites fluid with high prevalence: results from a randomized phase IIIb study
    Martinius, H.
    Biesterfeld, S.
    Seitz-Merwald, I
    Hennig, M.
    Seimetz, D.
    Boecking, A.
    ONKOLOGIE, 2011, 34 : 168 - 168
  • [48] Multi-omic analyses-based therapeutic development using tumor cells derived from ascites
    Tanaka, Yosuke
    CANCER SCIENCE, 2025, 116 : 758 - 758
  • [49] ESTABLISHMENT OF CELL LINES IN VITRO FROM A MAMMARY ASCITES TUMOR OF MOUSE AND BIOLOGICAL PROPERTIES OF ESTABLISHED LINES IN A SERUM CONTAINING MEDIUM
    NAKANO, N
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 1966, 88 (01): : 69 - 84
  • [50] PROTEIN COMPOSITION OF EXTRACELLULAR VESICLES FROM MALIGNANT ASCITES DEFINES THE KEY COMPONENTS OF TUMOR MICROENVIRONMENT AND PREDICTS PROGNOSIS OF OVARIAN CANCER PATIENTS
    Kotrbova, Anna Vyhlidalova
    Gomoryova, Kristina
    Mikulova, Antonia
    Plesingerova, Hana
    Kravec, Marek
    Potesil, David
    Bleriot, Camille
    Bied, Mathilde
    Dunsmore, Garett
    Kotoucek, Jan
    Bednarikova, Marketa
    Hausnerova, Jitka
    Minar, Lubos
    Crha, Igor
    Felsinger, Michal
    Zdrahal, Zbynek
    Ginhoux, Florent
    Weinberger, Vit
    Bryja, Vitezslav
    Pospichalova, Vendula Hlavackova
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A285 - A286